Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Natural killer cell therapy - CellProtect Nordic Pharmaceuticals

Drug Profile

Natural killer cell therapy - CellProtect Nordic Pharmaceuticals

Alternative Names: CellProtect

Latest Information Update: 10 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avaris
  • Developer Avaris; CellProtect Nordic Pharmaceuticals; Karolinska Institute; Sanofi
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma
  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 01 Jul 2021 Phase-II clinical trials in Multiple myeloma (Combination therapy, First-line therapy, In adults, In the elderly) in Sweden (IV) (NCT04558931)
  • 24 Sep 2020 NCT04558931: Update only, added FET for planned P-II trial, sent THES to replace MoA-Cell-replacements with Natural-killer-cell-replacements
  • 22 Sep 2020 Karolinska Institutet in collaboration with Sanofi plans a phase II trial for Multiple myeloma (Combination therapy, First-line therapy, In adults, In the elderly) in Sweden (IV) in October 2020 (NCT04558931)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top